IMATINIB MESYLATE

USDailyMed:Imatinib AU:D L01EA01(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide 152459-95-5Y220127-57-1(mesilate) 5291 5687 DB00619Y 5101Y BKJ8M8G5HI D08066Y CHEBI:45783Y ChEMBL941Y STI (PDBe,RCSB PDB) DTXSID3037125 Interactive image Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,3‍‍‍‍‍‍​​​‍​​​​​​1,33,34)YKey:KTUFNOKKBVMGRW-UHFFFAOYSA-NY Imatinib, sold under the brand namesGleevecandGlivec(both marketed worldwide byNovartis) among others, is an oraltargeted therapymedication used to treatcancer.Imatinib is a small molecule inhibitor targeting multipletyrosine kinasessuch asCSF1R,ABL,c-KIT,FLT3, andPDGFR-β.Specifically, it is used forchronic myelogenous leukemia(CML) andacute lymphocytic leukemia(ALL) that arePhiladelphia chromosome–positive (Ph+), certain types ofgastrointestinal stromal tumors(GIST),hypereosinophilic syndrome(HES),chronic eosinophilic leukemia(CEL),systemic mastocytosis, andmyelodysplastic syndrome. Common side effects include vomiting, diarrhea, muscle pain, headache, and rash. Severe side effects may includefluid retention,gastrointestinal bleeding,bone marrow suppression,liver problems, andheart failure. Use duringpregnancymay result in harm to the baby. Imatinib works bystopping the Bcr-Abl tyrosine-kinase. This can slow growth or result inprogrammed cell deathof certain types of cancer cells. Imatinib was approved for medical use in the United States in 2001.It is on theWorld Health Organization's List of Essential Medicines.A generic version became available in the UK as of 2017.